Akebia Therapeutics, Inc. AKBA
0.53 USD -0.05 (-8.04%)
Nov 12, 2026, 2:33 PM EST
0.5163 Day range 0.5713
0.361 52-week range 1.84
- YTD
- -67.23%
- 1 year
- -71.48%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.
seekingalpha.com Akebia Therapeutics, Inc. (AKBA) Q3 2026 Earnings Call Transcript Akebia Therapeutics, Inc. ( AKBA ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler -…
benzinga.com BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3 BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
marketbeat.com What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call Akebia Therapeutics NASDAQ: AKBA reported lower third-quarter revenue and a net loss as sales of its kidney disease drug Auryxia fell and inventory reductions limited revenue growth for its anemia…
zacks.com Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
benzinga.com Akebia Therapeutics Q3 2026 Earnings Call Transcript Akebia Therapeutics (NASDAQ:AKBA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Akebia Therapeutics Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $36.900M Miss $46.941M Estimate Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $36.900…
globenewswire.com Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
globenewswire.com Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s…- benzinga.com BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
benzinga.com Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027- benzinga.com WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5 WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.
benzinga.com Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations but lowers guidance. Other stocks dip in pre-market.
benzinga.com Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
benzinga.com Akebia Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $49.128M Beat $48.861M Estimate Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $49.128…- benzinga.com Akebia Therapeutics Initiates Phase 2 Basket Trial To Evaluate Safety, Efficacy, And Pharmacokinetics Of Ebribafusp For Treatment Of Rare Complement-Mediated Kidney Diseases Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket…
benzinga.com HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $6 price target.- benzinga.com Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafseo Outcomes In Center Experience Study After Planned Interim Analysis Based On Recommendation From Independent Data Monitoring Committee, Trial Steering Committee Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and U.S. Renal Care (USRC), the nation’s largest…
benzinga.com Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and…
benzinga.com Akebia Therapeutics Q1 EPS $(0.03), Inline, Sales $53.544M Beat $51.668M Estimate Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 200 percent decrease over earnings of $0.03 per share from the…- benzinga.com Akebia Therapeutics Announces Publication Of Post-Hoc Win Statistics Analysis Of All-Cause Mortality And Hospitalization From Its Global Phase 3 INNO2VATE Program In The Journal Of The American Society Of Nephrology "The win statistics analysis highlighted favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensure informed clinical decision-making for nephrologists…
- benzinga.com Akebia Therapeutics Doses First Patient In Phase 1 Clinical Study Of AKB-9090 To Treat Cardiac Surgery-Associated Acute Kidney Injury Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been…
- benzinga.com BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
benzinga.com Akebia Therapeutics Q4 Earnings Report: What Investors Need to Know - benzinga.com Akebia Therapeutics Q4 EPS $(0.05) Misses $(0.03) Estimate, Sales $57.620M Beat $48.373M Estimate. Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.03) by 85.19 percent. This is a 50 percent increase over losses of…
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Uncovering Potential: Akebia Therapeutics's Earnings Preview 
benzinga.com Where Akebia Therapeutics Stands With Analysts - benzinga.com BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4 BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $5 to $4.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session